STOCK TITAN

Insmed (INSM) Stock News

INSM NASDAQ

Insmed Incorporated develops and commercializes biopharmaceutical therapies for serious diseases, with a commercial respiratory portfolio that includes ARIKAYCE® (amikacin liposome inhalation suspension) and BRINSUPRI® (brensocatib). Its pipeline spans pulmonary, inflammatory, immunology and rare-disease programs, including TPIP and INS1148, alongside early research in gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining and synthetic rescue.

Recurring company news covers product revenue trends, regulatory authorizations and label-development activity for ARIKAYCE and BRINSUPRI, clinical data in MAC lung disease, non-cystic fibrosis bronchiectasis and inflammatory conditions, and presentations at medical and investor conferences. Updates also include portfolio-prioritization decisions, financial results, employee equity inducement grants and other governance-related announcements.

Rhea-AI Summary

Insmed (Nasdaq: INSM) announced that management will present at investor conferences in November and December 2026 in London and Coral Gables.

The Jefferies Global Healthcare Conference presentation is November 16 at 2:00 p.m. GT / 9:00 a.m. ET. The Evercore 9th Annual Healthcare Conference presentation is December 1 at 9:10 a.m. ET. Live webcasts will be available through Insmed's investor relations website, with archives available for 30 days after each event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.32%
Tags
none
-
Rhea-AI Summary

Insmed (INSM) reported third-quarter 2026 revenue of $524.4 million and raised its full-year revenue guidance for both commercial products. Revenue increased 268% year over year. BRINSUPRI sales reached $400.1 million, up 29% sequentially; ARIKAYCE sales rose 9% year over year to $124.4 million. Net loss narrowed to $100.3 million, or $0.46 per share, from $370.0 million, or $1.75 per share.

Insmed now expects 2026 BRINSUPRI revenue of $1.35 billion–$1.4 billion and ARIKAYCE revenue of $460 million–$470 million, raising both lower bounds. BRINSUPRI launched in Japan in October following August approval for non-cystic fibrosis bronchiectasis in patients aged 12 and older. The FDA accepted ARIKAYCE's application for expanded use in MAC lung disease, granting Priority Review with a January 28, 2027 target action date. Cash, cash equivalents and marketable securities totaled approximately $1.1 billion at September 30.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.06%
Tags
-
Rhea-AI Summary

Insmed (INSM) appointed Paul Hudson and Utpal Koppikar as independent members of its Board of Directors, effective immediately.

Hudson served as CEO of Sanofi from September 2019 through February 2026 and previously led Novartis Pharmaceuticals from 2016 to 2019. Koppikar has served as CFO of Verily Health since April 2023, following his role as executive vice president and CFO at Atara Biotherapeutics from 2018 to 2023. He also serves on the board of C4 Therapeutics (CCCC). Insmed said the appointments add global commercial strategy and financial management experience to its board.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.40%
Tags
management
Rhea-AI Summary

Insmed (INSM) has commercially launched BRINSUPRI in Japan as a prescription treatment for non-cystic fibrosis bronchiectasis, a chronic lung disease. BRINSUPRI Tablets 25 mg (brensocatib hydrate) is an oral, once-daily treatment approved for adults and pediatric patients 12 years and older. Japan's Ministry of Health, Labour, and Welfare approved the medicine in August 2026.

The treatment inhibits DPP1, an enzyme involved in activating proteins that drive chronic airway inflammation. BRINSUPRI is also approved in the United States in 10 mg and 25 mg tablets for patients aged 12 and older. European Union and United Kingdom approvals cover 25 mg tablets for patients aged 12 and older who have had two or more exacerbations in the prior 12 months; exacerbations are episodes of worsening disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
none
-
Rhea-AI Summary

Insmed (INSM) has initiated three Phase 3 studies of treprostinil palmitil inhalation powder (TPIP) within its global PALM development program. The program evaluates once-daily TPIP across pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), progressive pulmonary fibrosis (PPF), and idiopathic pulmonary fibrosis (IPF).

PALM-PAH, PALM-ILD and PALM-PPF have begun; Insmed expects PALM-IPF to begin in the first half of 2027 and aims to enroll more than 2,000 patients across the program. The PAH and PH-ILD studies measure change in six-minute walking distance at Week 24. The PPF and planned IPF studies assess change in forced vital capacity, a measure of lung function, at Week 52, with treatment lasting 52 to 104 weeks. Insmed will feature the program at CHEST 2026. TPIP remains investigational and is not approved in any jurisdiction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
-
Rhea-AI Summary

Insmed (INSM) will present respiratory portfolio data at CHEST 2026 on October 18–21 and IDWeek 2026 on October 21–24.

CHEST, held in Phoenix, will feature four abstracts from the treprostinil palmitil inhalation powder (TPIP) development program, including three late-breaking abstracts. Topics include imaging correlations and extension studies in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. A separate analysis of the Phase 3 ASPEN study of BRINSUPRI examines patient-reported sputum color and its association with inflammatory enzymes and exacerbations.

At IDWeek in Washington, D.C., two ARIKAYCE presentations will cover antibiotic resistance in newly diagnosed Mycobacterium avium complex lung disease from the Phase 3b ENCORE study, and real-world evidence on treatment drivers and outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
none
News
Rhea-AI Summary

Insmed (INSM) announced that Sara Bonstein will step down as chief financial officer on October 30, 2026.

Bonstein will remain in the role through third-quarter financial reporting and participate in the October 29 earnings call. Insmed has begun a search for her successor with an executive search firm. Bonstein said she intends to pursue a broader leadership role after nearly seven years at the company.

Insmed reaffirmed its full-year 2026 revenue guidance of $1.25 billion to $1.40 billion for BRINSUPRI and $450 million to $470 million for ARIKAYCE. The company expects to reach cash flow positivity next year. Third-quarter results will be released on October 29, 2026, followed by a management conference call at 8:00 a.m. ET to discuss results and provide a business update.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.56%
Tags
none
-
Rhea-AI Summary

Insmed (INSM) received FDA Priority Review for its supplemental New Drug Application (sNDA) seeking full approval of ARIKAYCE (amikacin liposome inhalation suspension) to treat Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial regimen, with a PDUFA target action date of January 28, 2027.

The filing aims to move ARIKAYCE use earlier in the disease course, including newly diagnosed and recurrent infections, and would also fulfill the post‑marketing requirement from ARIKAYCE’s 2018 accelerated approval under the Limited Population Pathway for Antibacterial and Antifungal Drugs. The sNDA is supported by the randomized, double‑blind, placebo‑controlled Phase 3b ENCORE study in 425 treatment‑naïve MAC lung disease patients, where ARIKAYCE plus multidrug therapy met its primary endpoint of improved Respiratory Symptom Score at Month 13 and multiplicity‑controlled secondary culture conversion endpoints versus multidrug therapy alone, with a safety profile consistent with prior experience. Insmed plans to discuss ENCORE data with Japan’s PMDA in Q4 2026 for potential label expansion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
none
-
Rhea-AI Summary

Insmed (INSM) is holding its fifth annual Global Day of Good on September 16, 2026, a company-wide day of service involving employees worldwide.

The 2026 event is described as the largest yet, with more than 1,350 employees across the U.S., Europe, and Japan participating in 50 activities that benefit over 50 nonprofit organizations. Volunteer efforts focus on health, education, and human services, ranging from STEM kit assembly and food bank support to environmental cleanups, care packages for children with serious diseases, book translation, student wellbeing workshops, and bicycle refurbishment. Over five years, employees have logged about 15,000 volunteer hours through this initiative.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
none
Rhea-AI Summary

Insmed (INSM) granted equity inducement awards to 128 new employees under its 2025 Inducement Plan, designed to comply with Nasdaq Listing Rule 5635(c)(4).

Effective August 31, 2026, the employees received a total of 115,320 restricted stock units and options to purchase an aggregate 5,560 shares of Insmed common stock at an exercise price of $121.82 per share, equal to the closing trading price on the grant date. The restricted stock units vest over four years in equal 25% annual installments, starting on the first anniversary of the first day of the month following the grant date, subject to continued service.

The stock options have a 10-year term and a four-year vesting schedule, with 25% vesting on the first such anniversary and 12.5% vesting every six months thereafter through the fourth anniversary, also contingent on continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none

FAQ

What is the current stock price of Insmed (INSM)?

Insmed (INSM) last closed at $141.33.

What is the market cap of Insmed (INSM)?

The market cap of Insmed (INSM) is approximately $31.0B.